4.7 Article

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam

期刊

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.02179-21

关键词

KPC; carbapenemase

资金

  1. Antimicrobial Resistance Cross Council Initiative [MR/S004769/1]
  2. National Institute for Health Research
  3. University of Bristol

向作者/读者索取更多资源

The study reveals a variant of Klebsiella pneumoniae that exhibits resistance to multiple antibiotics, including ceftazidime-avibactam and meropenem-vaborbactam. Further mutations and enzyme production are required for resistance to other antibiotics.
We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazidime-avibactam plus aztreonam and imipenem-relebactam but not cefepime-taniborbactam. The V239G variant does not generate collateral beta-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据